SurModics Inc.+$0.72 $11.65 A Rodman & Renshaw analyst upgraded the shares to "market perform," saying the share price already reflects the risks the medical technology company is facing. (Ticker: SRDX)
Most Read
-
Why Minnesota millennials feel worse off than their parents
-
Minnesotans find Xcel's dynamic pricing plan too aggressive, not worth energy savings
-
Target cuts prices on thousands of basic items to lure budget shoppers away from Walmart
-
Minnesotans among least likely to climb income ladder in U.S.
-
Rochester company uses AI to create virtual mannequins for hard-to-fit bodies